Coya Therapeutics’ (COYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Monday,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock. HC Wainwright also issued estimates for Coya Therapeutics’ Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.52) EPS.

A number of other research firms have also recently issued reports on COYA. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, January 8th. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, January 21st. BTIG Research raised their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital restated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Down 2.1%

NASDAQ COYA opened at $4.76 on Monday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29. The company’s 50-day simple moving average is $5.33 and its 200 day simple moving average is $5.87. The stock has a market cap of $99.58 million, a P/E ratio of -4.29 and a beta of 0.27.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $3.70 million. Research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of the stock. CM Management LLC boosted its holdings in shares of Coya Therapeutics by 16.7% in the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after buying an additional 50,000 shares during the last quarter. Dauntless Investment Group LLC raised its stake in Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after purchasing an additional 101,932 shares in the last quarter. Citadel Advisors LLC lifted its position in shares of Coya Therapeutics by 51.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares during the period. Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after buying an additional 13,176 shares in the last quarter. Finally, Prosperity Wealth Management Inc. raised its position in Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.